ImmUniverse
Improved diagnostic and therapeutic options for patients living with ulcerative colitis and atopic dermatitis: this is the ultimate aim of the ImmUniverse project.
New insights into disease severity and progression will enable personalised therapy for each individual patient.
ImmUniverse is an ambitious multi-national research project aimed to improve diagnostic and therapeutic solutions for two immune-mediated diseases: ulcerative colitis (in which the immune system attacks the colon), and atopic dermatitis (which affects the skin). The Regenerative Technologies Lab is part of the project developing innovative ultrasonic stimulation technologies and software models for performing a “wireless biopsy” (non-invasive) for a personalized diagnosis in patients with ulcerative colitis.
More info @ https://www.immuniverse.eu/
THE CONSORTIUM
Humanitas University, Italy
AIT Austrian Institute of Technology GmbH, Austria
Istituto Superiore di Sanità (Italian NIH), Italy
Christian-Albrechts-Universität zu Kiel, Germany
University of Cambridge, UK
Amsterdam UMC – Academic Medical Centre Amsterdam, The Neetherlands
Vlaams Instituut voor Biotechnologie (Flemish Institute for Biotechnology), Belgium
Katholieke Universiteit Leuven, Belgium
Ludwig-Maximilian University, Germany
Aarhus University, Austria
Aarhus University Hospital, Austria
University of Luxembourg, Luxembourgh
Joanneum Research Forschungsgesellschaft mbH, Austria
Radboud University Medical Center, Radboudumc, The Neetherlands
Centre Hospitalier Régional Universitaire Nancy, France
Information Technology for Translational Medicine S.A., Luxembourgh
European Patients’ Forum, Germany
European Federation of Allergy and Airways Diseases Patients’ Associations
European Federation of Crohn’s and Ulcerative Colitis Associations, The Neetherlands
European Research and Project Office GmbH, Germany
Sant’Anna School of Advanced Studies, Italy
GlaxoSmithKline Research and Development Ltd., UK
Sanofi-Aventis Deutschland GmbH, Germany
Eli Lilly and Company Limited, UK
Novartis Pharma AG, Switzerland
Pfizer Ltd, UK
